Nanomedicine is a developing discipline that is constantly evolving and differentiating.Liposomal preparation has an important role in nanomedicine as a novel platform. QbD involves drug formulation and advancement of a pharmaceutical medicament, including understanding of product quality and formulation steps, processing, and implementing controlsto establish the product quality maintained by QbD. Primarily, drug and medicament governing bodies, including the USA and FDA, enhance product quality. Liposomal formulations and optimisation involve dependent and independent variables, requiring experience in optimisation. QbD is a risk-based approach used early in the pharmaceutical process to improveproduct quality and efficacy. Please shorten the given text so that it is more concise. QbD speeds up product development and ensures consistent, safe drug formulation in complex systems. In QbD, steps flow as adding variables related to CMAs, CPPs, and design places responsible for quality attributes for the final liposomal product preparation. QbD has recentlybeen proposed as a tool for obtaining higher-quality liposomal nanocarriers. The broader structure of this research discusses the involvement of QbD as recent approach including their different parameters. Overall, lastly, the current practices that employ QbD in the optimisation and formulation of doxorubicin (DOX), by the using thin film-hydration extrusion technique primarily. DOX is antitumor class drug with a brand (Doxil®) loaded liposomal with TNF receptor as nanocarrier optimisation and formulation.